Patents Assigned to ACADEMY OF MILITARY MEDICAL SCIENCES
  • Patent number: 11738000
    Abstract: Disclosed are hydroquinone compounds, preparation methods therefor, and uses thereof in anti-tumor or immunomodulation. The structural formula of the hydroquinone compounds are shown by formula I, wherein X is C?O or CH2; Y is NH, O or absent; R is: a substituted or unsubstituted alkyl group having at least one carbon atom, a substituted or unsubstituted cycloalkyl group having at least three carbon atoms, a substituted or unsubstituted alkenyl group or alkynyl group having at least two carbon atoms; and a substituted or unsubstituted aryl group or heteroaryl group containing at least four carbon atoms. The compounds provided slowly release 2-tert-butyl-4-methoxyphenol in vivo and maintain stable plasma concentration of 2-tert-butyl-4-methoxyphenol (T1/2=12-24 h). The compounds provided by the present invention protect the phenolic hydroxyl group of 2-tert-butyl-4-methoxyphenol, avoids environmental oxidation and increase the environmental stability of drugs containing the compounds.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: August 29, 2023
    Assignees: BIOMEDICAL ANALYSIS CENTER, ACADEMY OF MILITARY MEDICAL SCIENCES, INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY, ACADEMY OF MILITARY MEDICAL SCIENCES
    Inventors: Xuemin Zhang, Xinhua He, Tao Zhou, Zhenggang Liu, Tao Li
  • Publication number: 20230250489
    Abstract: The present disclosure relates to a biomarker, a kit, and a method for detection or auxiliary detection of proton irradiation and use thereof, and belongs to the field of biotechnology. The present disclosure provides a microbial biomarker for detection or auxiliary detection of proton irradiation, in which the microbiota includes at least one of Cyanobacteria, Epsilonbacteraeota, Anaerovorax and Helicobacter. In the present disclosure, whether a subject to be tested is exposed to proton radiation is accurately determined by detection of an abundance or relative abundance of DNA of the microbial biomarker. This is conductive to timely accident rescue, casualty treatment and clinical treatment application, which is of great significance to radiation treatment.
    Type: Application
    Filed: December 20, 2022
    Publication date: August 10, 2023
    Applicant: Academy of Military Medical Sciences
    Inventors: Hua GUAN, Shanshan Gao, Pingkun Zhou, Chenjun Bai, Yuchen Li, Hongling Zhao, Wen Zhang, Xiaochang Liu
  • Patent number: 11655201
    Abstract: The present invention relates to a stable crystal form, i.e. form A, of 2-tert-butyl-4-methoxyphenol, and to a new preparation method for the 2-tert-butyl-4-methoxyphenol; and the use of the 2-tert-butyl-4-methoxyphenol and the stable crystal form thereof, i.e. form A, in preparing antitumor drugs or immunomodulator drugs. The stable crystal form, i.e. form A, as expressed by a powder X-ray diffraction pattern in an angle of 2?, using Cu-K? radiation, has at least 3 absorption peaks selected from the following positions: 6.27±0.10, 6.94±0.10, 12.27±0.10, 13.36±0.10, 14.01±0.10, 14.79±0.10, 15.31±0.10, 17.05±0.10, 18.30±0.10, 19.00±0.10, 20.47±0.10, 20.98±0.10, 22.37±0.10, 23.68±0.10, 24.55±0.10, 25.37±0.10, 30.83±0.10, 33.12±0.10, 40.50±0.10, 42.81±0.10.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: May 23, 2023
    Assignee: BIOMEDICAL ANALYSIS CENTER, ACADEMY OF MILITARY MEDICAL SCIENCES
    Inventors: Xuemin Zhang, Xinhua He, Tao Zhou, Zhenggang Liu, Tao Li, Shengming Wu
  • Publication number: 20230022109
    Abstract: Provided is a novel coronavirus vaccine using replication-deficient human type 5 adenovirus as a vector. The vaccine takes the replication-deficient human type 5 adenovirus that is lack of E1 and E3 in a combined mode as a vector, and HEK293 cells that integrate adenovirus E1 genes serve as a packaging cell line, and protective antigenic genes carried are optimized COVID-19 (SARS-CoV-2) S protein genes (Ad5-nCoV). The vaccine has good immunogenicity in both mouse and guinea pig models and can induce the body to produce a strong cellular and humoral immune responses in a short time. Research on the protective effect of hACE2 transgenic mice shows that 14 days after a single Ad5-nCoV immunization, the viral load in lung tissues can be significantly reduced. It shows that the vaccine has a good immune protection effect against COVID-19.
    Type: Application
    Filed: June 15, 2020
    Publication date: January 26, 2023
    Applicants: ACADEMY OF MILITARY MEDICAL SCIENCE, PLA, CANSINO BIOLOGICS INC.
    Inventors: Wei Chen, Shipo Wu, Lihua Hou, Zhe Zhang, Busen Wang, Qiang Guo, Jinlong Zhang, Xiaohong Song, Ling Fu, Jun Zhang, Yi Chen, Zhenghao Zhao, Tao Zhu, Jin Li, Chunlin Xin
  • Publication number: 20220315949
    Abstract: A single plasmid vector system for packaging recombinant human adenovirus type 4. The vector system contains an E3 region-deleted human adenovirus type 4 (HAdV-4 or Ad4) genome, a vector sequence for amplifying plasmids in bacteria, a pBR322 replication origin, a kanamycin resistance gene, and a replication control sequence; and an exogenous gene embedding site is located behind a packaging signal of the human adenovirus type 4 and in front of an E1 region. The present invention further provides a method for packaging the recombinant human adenovirus type 4 by the single plasmid vector system and an application in vaccine and drug preparation. The vector system can be used for rapidly and efficiently preparing a human adenovirus type 4 vector recombinant virus for stably expressing an exogenous gene, and has a good application prospect in the fields of preparation of a diagnostic kit, a vaccine, a gene therapy kit and/or a tumor therapy drug, etc.
    Type: Application
    Filed: September 26, 2019
    Publication date: October 6, 2022
    Applicant: ACADEMY OF MILITARY MEDICAL SCIENCE, PLA
    Inventors: Wei Chen, Busen Wang, Lihua Hou, Shipo Wu, Qiang Guo, Zhe Zhang, Zhenghao Zhao, Jinlong Zhang, Ling Fu, Xiaohong Song
  • Patent number: 11453704
    Abstract: The present invention relates to a nucleotide sequence as shown in SEQ ID NO: 1 for encoding a Marburg virus envelope glycoprotein, and to a human replication-deficient recombinant adenovirus capable of expressing the nucleotide sequence and a preparation method therefor, as well as an application thereof in the preparation of a vaccine against Marburg virus disease. The vaccine uses an E1 and E3 deleted replication-deficient human type-5 adenovirus as a vector, and HEK293 cells integrating an adenovirus E1 gene as a packaging cell line, and a protective antigen gene carried is a codon-optimized Marburg virus Angola strain envelope glycoprotein gene. After codon optimization of the envelope glycoprotein gene, significant expression of envelope glycoprotein can be detected in transfected cells.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: September 27, 2022
    Assignee: Academy of Military Medical Science, PLA
    Inventors: Wei Chen, Shipo Wu, Lihua Hou, Yanbo Wen, Zhe Zhang, Busen Wang, Xiaohong Song, Jinlong Zhang, Ling Fu
  • Patent number: 11369587
    Abstract: The present invention relates to a pharmaceutical composition of Tecovirimat for injection, comprising Tecovirimat as an active ingredient, cyclodextrin and an additive. The present invention also relates to a method for preparing the pharmaceutical composition. The composition improves the solubility of Tecovirimat in water by using cyclodextrin and meglumine in combination, as compared with the solubility of Tecovirimat in water by using cyclodextrin or meglumine alone.
    Type: Grant
    Filed: July 4, 2017
    Date of Patent: June 28, 2022
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences PLA China
    Inventors: Wu Zhong, Meiyan Yang, Wei Gong, Yuli Wang, Chunsheng Gao, Xinbo Zhou, Song Li
  • Publication number: 20220193039
    Abstract: Related is application of 2,4,5-trisubstituted 1,2,4-triazolones in antiviral therapy, particularly related to use of a compound of formula I in the preparation a medicament, wherein the medicament is used to prevent and/or treat a disease associated with a virus.
    Type: Application
    Filed: July 15, 2021
    Publication date: June 23, 2022
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Xinbo ZHOU, Ruiyuan CAO, Dian XIAO, Manli WANG, Shiyong FAN, Zhihong HU, Song LI
  • Patent number: 11318135
    Abstract: The present application relates to a Favipiravir compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for treating a coronavirus infection.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: May 3, 2022
    Assignee: Academy of Military Medical Sciences
    Inventors: Wu Zhong, Ruiyuan Cao, Cheng Cao, Ting Gao, Gengfu Xiao, Zhihong Hu, Manli Wang, Leike Zhang, Song Li
  • Patent number: 11318115
    Abstract: The present invention relates to a pharmaceutical composition, comprising Tecovirimat, cyclodextrin and an additive, and optionally a pharmaceutically acceptable excipient. The present invention also relates to a method for preparing the pharmaceutical composition. The composition improves the solubility of Tecovirimat in water by using cyclodextrin and meglumine in combination, as compared with the solubility of Tecovirimat in water by using cyclodextrin or meglumine alone.
    Type: Grant
    Filed: July 4, 2017
    Date of Patent: May 3, 2022
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Wu Zhong, Meiyan Yang, Wei Gong, Yuli Wang, Chunsheng Gao, Xinbo Zhou, Song Li
  • Publication number: 20220105077
    Abstract: Related is application of 2,4,5-trisubstituted 1,2,4-triazolones in antiviral therapy, particularly related to use of a compound of formula I in the preparation a medicament, wherein the medicament is used to prevent and/or treat a disease associated with a virus.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 7, 2022
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Xinbo ZHOU, Ruiyuan CAO, Dian XIAO, Manli WANG, Shiyong FAN, Zhihong HU, Song LI
  • Patent number: 11260031
    Abstract: The present invention relates to a protein particle with a poorly water-soluble drug encapsulated therein and a preparation method therefor. The preparation method comprises the following steps: i) dissolving a poorly water-soluble drug and a liquid solubilizer into a good solvent; ii) partially or fully removing said good solvent from the product of step i); iii) mixing the product of step ii) with a protein; and iv) dispersing the product of step iii) in a poor solvent. The preparation method is simple and is suitable for industrial production.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: March 1, 2022
    Assignee: ACADEMY OF MILITARY MEDICAL SCIENCES
    Inventors: Zhiping Li, Zhenbo Yang, Yang Yang, Fanglin Yu, Wei Gong, Meiyan Yang, Yuli Wang, Chunsheng Gao, Xingguo Mei
  • Patent number: 11205502
    Abstract: Provided are a processing method and a processing apparatus for efficacy of a combined drug. The processing method includes: obtaining dose-effect curve band of expected additive effect of the combined drug; obtaining actual dose-effect relationship curve formed by actual effect value of the combined drug with a dose change of one target component drug in the combined drug; comparing a positional relationship between the actual dose-effect relationship curve and the dose-effect curve band; and outputting the efficacy of the combined drug as a synergistic effect when the actual dose-effect relationship curve is located above the dose-effect curve band, outputting the efficacy of the combined drug as an antagonistic effect when the actual dose-effect relationship curve is located below the dose-effect curve band, and outputting the efficacy of the combined drug as an additive effect when the actual dose-effect relationship curve is located within a range of the dose-effect curve band.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: December 21, 2021
    Assignee: Institute of radiation medicine, academy of military medical sciences, PLA.
    Inventors: Shoujun Yuan, Linna Li, Dexuan Yang
  • Patent number: 11180463
    Abstract: The present invention pertains to field of pharmaceutical chemicals, and relates to thiazole inner salt compounds, preparation methods and uses thereof. Specifically, the present invention relates to a compound of Formula I, hydrates or pharmaceutically acceptable salts thereof. The compound of Formula I of the present invention is a potent cross-linking protein cleavage agent, has a stable structure, good physical and chemical properties, and good pharmacological activities, and is suitable for large scale production to obtain samples with stable, controllable and reliable quality, thereby being suitable for pharmaceutical development.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: November 23, 2021
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song Li, Wu Zhong, Shuang Cao, Lili Wang, Zhibing Zheng, Junhai Xiao, Xinbo Zhou
  • Publication number: 20210346376
    Abstract: The present application relates to a Favipiravir compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for treating a coronavirus infection.
    Type: Application
    Filed: July 16, 2021
    Publication date: November 11, 2021
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Ruiyuan CAO, Cheng CAO, Ting GAO, Gengfu XIAO, Zhihong HU, Manli WANG, Leike ZHANG, Song LI
  • Publication number: 20210346411
    Abstract: The present application relates to use of a substituted aminopropionate compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for the treatment of a disease or an infection caused by a SARS-CoV-2.
    Type: Application
    Filed: July 16, 2021
    Publication date: November 11, 2021
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Ruiyuan CAO, Gengfu XIAO, Zhihong HU, Manli WANG, Leike ZHANG, Wei LI, Yuexiang LI, Lei ZHAO, Shiyong FAN, Song LI
  • Patent number: 11149253
    Abstract: Provided are a small molecule compound combination for reprogramming digestive tract derived epithelial cells to endodermal stem/progenitor cells, a reprogramming method and an application. Human gastric epithelial cells (hGECs) are used as initiating cells, human gastric subepithelial myofibroblasts (aGSEMFs) are used as a trophoblast, a compound combination having all or a plurality of FBP, Bay K 8644, Bix01294, SB431542 or A813-01, VPA, RG108, PD0325901 and PS48 including SB or A83 is used to reprogram digestive tract derived epithelial cells to endodermal stem/progenitor cells, and the endodermal stem/progenitor cells can be used for inducing differentiation towards liver cells, pancreatic beta cells and intestinal cells.
    Type: Grant
    Filed: May 27, 2017
    Date of Patent: October 19, 2021
    Assignee: INSTITUTE OF TRANSFUSION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PEOPLE'S LIBRATION ARMY OF CHINA
    Inventors: Yunfang Wang, Shuyong Wang, Wencheng Zhang, Jinhua Qin, Xuan Wang, Mingyang Chang, Fang Yan, Xuetao Pei
  • Publication number: 20210220377
    Abstract: The present application relates to use of a substituted aminopropionate compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for the treatment of a disease or an infection caused by a SARS-CoV-2.
    Type: Application
    Filed: October 14, 2020
    Publication date: July 22, 2021
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Ruiyuan Cao, Gengfu Xiao, Zhihong Hu, Manli Wang, Leike Zhang, Wei Li, Yuexiang Li, Lei Zhao, Shiyong Fan, Song Li
  • Publication number: 20210220353
    Abstract: The present application relates to a Favipiravir compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for treating a coronavirus infection.
    Type: Application
    Filed: October 14, 2020
    Publication date: July 22, 2021
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Ruiyuan CAO, Cheng CAO, Ting GAO, Gengfu XIAO, Zhihong HU, Manli WANG, Leike ZHANG, Song LI
  • Patent number: 11066441
    Abstract: The present invention discloses a method for separating and purifying ?2-macroglobulin from Cohn Fraction IV precipitation, in which Cohn Fraction IV precipitation is treated by ammonium sulfate precipitation, zinc ion affinity chromatography, gel filtration, and ultrafiltration and concentration sequentially and thereby ?2-macroglobulin is obtained finally. With the method provided in the present invention, purified ?2-macroglobulin plasma protein that has a clinical application value is obtained, the Cohn Fraction IV precipitation is changed from a discarded material into a valuable material, and plasma is utilized comprehensively. In addition, the method is easy and simple to use, easy to scale up, and suitable for separation and purification of ?2-macroglobulin at a large scale.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: July 20, 2021
    Assignee: ACADEMY OF MILITARY MEDICAL SCIENCES
    Inventors: Yuyuan Ma, Chaoji Huangfu, Xiong Zhao, Maomin LV, Jingang Zhang, Junting Jia